Skip to content
value.today

Arsanis, Inc.

🇺🇸 Lebanon, New Hampshire, USABiotechnologyFounded 2010
Total raised
$110 M
5 rounds on record
Latest round
$20 M
Nov 2017
First round on record
Jan 2011
Today
Went public
See the company page

Arsanis, Inc. is listed today as X4 Pharmaceuticals, Inc.: market value, financials and filings are on its company page.

Funding rounds

5 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Arsanis, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2025$85 MPrivate placement after listing$50 to $250 million

Arsanis, Inc.: Private sale, Aug 2025

Investors in this round

18 investors had bought by the notice of Aug 25, 2025: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 28 investors are named for Arsanis, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$85 M of $85 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$3,300,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Adam Craig · Executive Officer, Director
  • Christophe Arbet-Engels · Executive Officer
  • David Kirske · Executive Officer
  • John Volpone · Executive Officer
  • Mark Baldry · Executive Officer
  • Mary DiBiase · Executive Officer
  • Francoise J. De Craecker · Director
  • Gary J. Bridger · Director
  • Michael S. Wyzga · Director
  • Murray W. Stewart · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • STIFEL, NICOLAUS & COMPANY, INCORPORATED (CRD 793) · St. Louis, MissouriSold in all US states, and outside the US

Signed by Natasha Thoren, Chief Legal Officer. Source: SEC Form D, newest notice filed Aug 25, 2025. Read the notice at the SEC.

equity, optionsSEC
May 2023$65 MPrivate placement after listing$50 to $250 million

Arsanis, Inc.: Private sale, May 2023

Investors in this round

22 investors had bought by the notice of Jun 1, 2023: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 28 investors are named for Arsanis, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$65 M of $65 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$4,000,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Adam Mostafa · Executive Officer
  • Arthur Taveras · Executive Officer
  • Mark Baldry · Executive Officer
  • Mary DiBiase · Executive Officer
  • Murray Stewart · Executive Officer, Director
  • Paula Ragan · Executive Officer, Director
  • Alison Lawton · Director
  • David McGirr · Director
  • Francoise de Craecker · Director
  • Gary Bridger · Director
  • Michael Wyzga · Director
  • William Aliski · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Cantor Fitzgerald & Co. (CRD 134) · New York, New YorkSold in CT, DE, FL, MA, MD, NY, OR
  • Piper Sandler & Co. (CRD 665) · Minneapolis, MinnesotaSold in CT, DE, FL, MA, MD, NY, OR
  • Stifel, Nicolaus & Company, Inc. (CRD 793) · Baltimore, MarylandSold in CT, DE, FL, MA, MD, NY, OR

Remarks in the notice

  • On the amounts: “"""Total Offering Amount"" includes amounts receivable by the Issuer upon the exercise of certain warrants to purchase the Issuer's Common Stock (assuming no cashless exercise)."”

Signed by Adam Mostafa, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 1, 2023. Read the notice at the SEC.

equity, optionsSEC
Jul 2022$56 MPrivate placement after listing$50 to $250 million

Arsanis, Inc.: Private sale, Jul 2022

Investors in this round

23 investors had bought by the notice of Jul 19, 2022: 23 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 28 investors are named for Arsanis, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$56 M of $112 M offered; $56 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,800,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Adam S. Mostafa · Executive Officer · Chief Financial Officer and Treasurer
  • Arthur S. Taveras · Executive Officer · Chief Scientific Officer
  • Derek S. Meisner · Executive Officer · Chief Legal Officer and Corporate Secretary
  • Diego S. Cadavid · Executive Officer · Chief Medical Officer
  • Mary S. DiBiase · Executive Officer · Chief Operating Officer
  • Paula Ragan · Executive Officer, Director
  • Alison E. Lawton · Director
  • David W. McGirr · Director
  • Francoise J. de Craecker · Director
  • Gary J. Bridger · Director
  • Michael S. Wyzga · Director
  • Murray W. Stewart · Director
  • William E. Aliski · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Stifel, Nicolaus & Company, Inc. (CRD 793) · Baltimore, MarylandSold in CT, IL, MA, MD, NY

Remarks in the notice

  • On the amounts: “"""Total Offering Amount"" includes amounts receivable by the Issuer upon the exercise of certain warrants to purchase the Issuer's Common Stock (assuming no cashless exercise)."”

Signed by Adam Mostafa, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 19, 2022. Read the notice at the SEC.

equity, optionsSEC
Nov 2017$20 MNo. 5$10 to $50 million

Arsanis, Inc.: Raise no. 5, Nov 2017

Investors in this round

1 investor had bought by the notice of Dec 4, 2017: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 28 investors are named for Arsanis, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M of $20 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,400,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Chris U. Stevens · Executive Officer
  • David U. Mantus · Executive Officer
  • Eszter U. Nagy · Executive Officer
  • Michael Gray · Executive Officer
  • Rene Russo · Executive Officer, Director
  • Amy U. Schulman · Director
  • Carl U. Gordon · Director
  • Claudio U. Nessi · Director
  • David U. McGirr · Director
  • Michael U. Ross · Director
  • Terrance U. McGuire · Director
  • Tillman U. Gerngross · Director
  • William U. Clark · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Citigroup Global Markets Inc. (CRD 7059) · New York, New YorkSold in MD
  • Cowen and Company, LLC (CRD 7616) · New York, New YorkSold in MD
  • Piper Jaffray & Co. (CRD 665) · Minneapolis, MinnesotaSold in MD

Signed by Michael Gray, Chief Operating Officer and Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 4, 2017. Read the notice at the SEC.

equitySEC
Apr 2017$46 MNo. 4$10 to $50 million

Arsanis, Inc.: Raise no. 4, Apr 2017

Investors in this round

18 investors had bought by the notice of May 8, 2017: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 28 investors are named for Arsanis, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$46 M of $51 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$3,000,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Chris U. Stevens · Executive Officer
  • David U. Mantus · Executive Officer
  • Eszter U. Nagy · Executive Officer, Director
  • Michael Gray · Executive Officer
  • Rene Russo · Executive Officer, Director
  • Tillman U. Gerngross · Executive Officer, Director
  • Amy U. Schulman · Director
  • Carl U. Gordon · Director
  • Claudio U. Nessi · Director
  • Dan U. Burgess · Director
  • Jan U. Adams · Director
  • Michael U. Ross · Director
  • Terrance U. McGuire · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael Gray, Chief Financial Officer. Source: SEC Form D, newest notice filed May 8, 2017. Read the notice at the SEC.

equitySEC
Apr 2016$15 MNo. 3$10 to $50 million

Arsanis, Inc.: Raise no. 3, Apr 2016

Investors in this round

10 investors had bought by the notice of Apr 27, 2016: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 28 investors are named for Arsanis, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$770,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eszter Nagy · Executive Officer, Director
  • Michael Gray · Executive Officer
  • Rene Russo · Executive Officer
  • Tillman Gerngross · Executive Officer, Director
  • Amy Schulman · Director
  • Carl Gordon · Director
  • Claudio Nessi · Director
  • Daniel Burgess · Director
  • Jan Adams · Director
  • Michael Ross · Director
  • Terrance McGuire · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Ordinary course compensation for services.”

Signed by Michael Gray, Chief Financial Officer. Source: SEC Form D, newest notice filed Apr 27, 2016. Read the notice at the SEC.

equity, debtSEC
Jul 2013$20 MNo. 2$10 to $50 million

Arsanis, Inc.: Raise no. 2, Jul 2013

Investors in this round

8 investors had bought by the notice of Jun 5, 2015: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 28 investors are named for Arsanis, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M of $20 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Eszter U Nagy · Executive Officer, Director
  • Tillman U Gerngross · Executive Officer, Director
  • Amy U Schulman · Director
  • Carl U Gordon · Director
  • Claudio U Nessi · Director
  • Dan U Burgess · Director
  • Michael U Ross · Director
  • Michael U Ross · Director
  • Terrance U McGuire · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jonathan Sheller, Treasurer. Source: SEC Form D and 2 amendments, newest notice filed Jun 5, 2015. Read the notice at the SEC.

equitySEC
Jan 2011$10 MNo. 1$2 to $10 million

Arsanis, Inc.: Raise no. 1, Jan 2011

Investors in this round

7 investors had bought by the notice of Feb 7, 2011: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 28 investors are named for Arsanis, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Errik B. Anderson · Executive Officer, Director
  • Robert L. Birnbaum · Executive Officer
  • Tillman U. Gerngross · Executive Officer, Director
  • Carl L. Gordon · Director
  • Michael L. Ross · Director
  • Terrance L. McGuire · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Robert L. Birnbaum, Secretary. Source: SEC Form D, newest notice filed Feb 7, 2011. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company X4 Pharmaceuticals, Inc., its revenue in fiscal 2025 came from these product and service lines: License and other revenue $28.59 million (81%).

    Annual report (SEC XBRL) · Dec 2025

  • Arsanis, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2025).

    SEC Form D · Aug 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2025

Products and services#

No products or services of Arsanis, Inc. are on record.

Investors#

28 named in official filings. Open an investor to see everything it has backed.

Investors in Arsanis, Inc.
InvestorKindAmountRoundRoleSource
Alexandria Venture Investments, LLCVenture capitalnot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Alphabet Inc.Fund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Anna-Maria & Stephen Kellen Foundation, Inc.Companynot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Bill & Melinda Gates FoundationOthernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
EMBL Technology Fund II GmbH & Co. KGFund or asset managernot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
EMBL Ventures Verwaltungs GmbHVenture capitalnot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
GV 2016 GP, L.L.C.Othernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
GV 2016 GP, L.P.Fund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
GV 2016, L.P.Fund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
NeoMed Innovation V L.P.Fund or asset managernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
NeoMed Innovation V LtdCompanynot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
NeoMed Management (Jersey) LtdFund or asset managernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
OrbiMed Capital GP IV LLCFund or asset managernot statednot statedHeld Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Polaris Venture Management Co. V, L.L.C.Venture capitalnot statednot statedHeld Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Polaris Venture Partners Entrepreneurs' Fund V, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Polaris Venture Partners Founders' Fund V, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Polaris Venture Partners Special Founders' Fund V, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Polaris Venture Partners V, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Section 32 Fund 1, LPFund or asset managernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Section 32 GP 1, LLCOthernot statednot statedHeld Series D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
SV Life Sciences Fund VI, L.P.Fund or asset managernot statednot statedHeld Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
SV Life Sciences Fund VI Strategic Partners, L.P.Fund or asset managernot statednot statedHeld Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
SV Life Sciences Fund V LPFund or asset managernot statednot statedHeld Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
SV Life Sciences Fund V Strategic Partners, L.P.Fund or asset managernot statednot statedHeld Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Svlsf VI, LLCOthernot statednot statedHeld Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Svlsf V, LLCOthernot statednot statedHeld Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2017)SEC Form 3
Tillman U. GerngrossPersonnot statednot statedHeld Series D preferred stock, 10% owner, director (Form 3, 2017)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 18 investors.

Largest shareholders today

Institutions holding X4 Pharmaceuticals, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Arsanis, Inc.
NameRoleNamed in
Adam CraigExecutive officerAug 2025
Christophe Arbet-EngelsExecutive officerAug 2025
David KirskeExecutive officerAug 2025
John VolponeExecutive officerAug 2025
Mark BaldryExecutive officerAug 2025
Mary DiBiaseExecutive officerAug 2025
Adam MostafaExecutive officerJun 2023
Arthur TaverasExecutive officerJun 2023
Murray StewartExecutive officerJun 2023
Paula RaganExecutive officerJun 2023
Adam S. MostafaChief Financial Officer and TreasurerJul 2022
Arthur S. TaverasChief Scientific OfficerJul 2022
Derek S. MeisnerChief Legal Officer and Corporate SecretaryJul 2022
Diego S. CadavidChief Medical OfficerJul 2022
Mary S. DiBiaseChief Operating OfficerJul 2022
Chris U. StevensExecutive officerDec 2017
David U. MantusExecutive officerDec 2017
Eszter U. NagyExecutive officerDec 2017
Michael GrayExecutive officerDec 2017
Rene RussoExecutive officerDec 2017
Tillman U. GerngrossExecutive officerMay 2017
Eszter NagyExecutive officerApr 2016
Tillman GerngrossExecutive officerApr 2016
Eszter U NagyExecutive officerJun 2015
Tillman U GerngrossExecutive officerJun 2015
Errik B AndersonExecutive officerAug 2014
Eszter B NagyExecutive officerAug 2014
Errik B. AndersonExecutive officerFeb 2011
Robert L. BirnbaumExecutive officerFeb 2011
Adam CraigDirectorAug 2025
Francoise J. De CraeckerDirectorAug 2025
Gary J. BridgerDirectorAug 2025
Michael S. WyzgaDirectorAug 2025
Murray W. StewartDirectorAug 2025
Alison LawtonDirectorJun 2023
David McGirrDirectorJun 2023
Francoise de CraeckerDirectorJun 2023
Gary BridgerDirectorJun 2023
Michael WyzgaDirectorJun 2023
Murray StewartDirectorJun 2023

Went public since 2017. Its SEC number is that of a company listed on a stock exchange.